Galmed Pharmaceuticals
GLMD
20 hedge funds and large institutions have $8.93M invested in Galmed Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
66% more capital invested
Capital invested by funds: $5.39M → $8.93M (+$3.54M)
33% more funds holding
Funds holding: 15 → 20 (+5)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAD
Craig A. Drill
|
+$913K |
| 2 |
Renaissance Technologies
New York
|
+$144K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$144K |
| 4 |
MC
Menta Capital
San Francisco,
California
|
+$120K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$917K |
| 2 |
Morgan Stanley
New York
|
-$156K |
| 3 |
6CM
683 Capital Management
New York
|
-$24K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$12K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$12K |
GLMD Hedge Fund Activity: Q1 2015 in Review
20 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q1 2015, worth a combined $8.93M — up 66% from $5.39M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new GLMD positions and 2 closed out — a net gain of 5 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Craig A. Drill, opening a new position worth an estimated $913K. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $917K sold.
- 20 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q1 2015, up from 15 in Q4 2014.
- Funds reported $8.93M of Galmed Pharmaceuticals stock for Q1 2015, up 66% quarter-over-quarter.
- 7 funds opened new Galmed Pharmaceuticals positions in Q1 2015 and 2 closed out, a net change of +5 holders.
- The largest Galmed Pharmaceuticals buyer in Q1 2015 was Craig A. Drill, an estimated $913K added.
- The largest Galmed Pharmaceuticals seller in Q1 2015 was DAFNA Capital Management, an estimated $917K sold.
Based on aggregated 13F filings for Q1 2015.